Cervical Cancer

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced cervical cancer.

Bintrafusp alfa induced responses in recurrent/metastatic cervical cancer, supporting the need for further research into TGF-β-targeted therapies.

A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

One of the first HPV self-collection solutions has been approved by the FDA, which can identify women at risk of developing cervical cancer.

The FDA has approved tisotumab vedotin-tftv for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Simple hysterectomy was shown to reduce the incidence of urinary incontinence vs radical hysterectomy for low-risk cervical cancer.

A priority review has been granted by the FDA to trastuzumab deruxtecan for the treatment of unresectable or metastatic HER2-positive advanced solid tumors.

Social support in patients with cervical cancer has the ability to provide patients with answers to some unknowns, and nurses can play a role in helping patients find this type of support.

With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”

Pembrolizumab plus chemoradiotherapy has been approved by the FDA for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.

A supplemental biologics license application has been granted priority review by the FDA, which seeks a full approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer that progressed on or following frontline therapy.

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.

The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.

The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.

Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.

Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.

Many Americans with health insurance are not fully covered for frontline procedures to treat lymphedema—a debilitating condition that often affects patients with cancer.

Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.

Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.

Patient navigation services increased the rates of breast, cervical, and colorectal cancer screenings 6-fold amongst women living in rural communities.

A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

Cervical cancer and precancers have decreased in recent years, thanks to the HPV vaccine.

The phase III AIM2CERV trial investigating axalimogene filolisbac (AXAL) in patients with cervical cancer has been placed on partial clinical hold by the FDA.

The presence of HPV-16 and -18 were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia (CIN) in women under the age of 30, study says.

The Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to expand its use in women and men aged 27 to 45 years.